Related Experiment Video
Updated: May 2, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Nintedanib for the treatment of non-small-cell lung cancer
1Indiana University, Indiana Cancer Pavilion, Hematology and Oncology , 535 Barnhill Dr. 473, Indianapolis, IN 46202 , USA +1 317 944 5000 ; nhanna@iu.edu.
Introduction:
In NSCLC, increased microvessel count, often used as a measure of angiogenesis, has been correlated with poor prognosis and associated with advanced disease and inferior outcomes. In the clinical development of antiangiogenic therapies, two approaches have been used; the first has been to inhibit ligand binding and receptor activation using targeted antibodies, whereas the second has been to inhibit receptor activation using tyrosine kinase inhibitors that target VEGF receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and/or fibroblast growth factor receptor (FGFR). Nintedanib is a triple angiokinase inhibitor that simultaneously acts on VEGFR, PDGFR and FGFR. It has shown significant antiangiogenic and antineoplastic activities in vitro, in preventing tumor growth and overcoming drug resistance.
Areas Covered:
Medline search was used with the following keywords: non-small-cell lung cancer and nintedanib or BIBF 1120, ASCO abstracts 2013 with nintedanib, and Phase I and Phase II abstracts lung cancer and nintedanib.
Expert Opinion:
Recent Phase III trials have shown promising efficacy results of nintedanib in NSCLC; however, many questions still need to be answered before it is put into routine use.
Insights
Nintedanib, a triple angiokinase inhibitor, shows promise in treating non-small cell lung cancer (NSCLC) by targeting angiogenesis. Further research is needed before its widespread clinical adoption.
Area of Science:
- Oncology
- Pharmacology
Background:
- Increased microvessel count in non-small cell lung cancer (NSCLC) correlates with poor prognosis.
- Antiangiogenic therapies target pathways like VEGF, PDGFR, and FGFR.
- Nintedanib is a triple angiokinase inhibitor targeting VEGFR, PDGFR, and FGFR, demonstrating anti-tumor activity in vitro.
Purpose of the Study:
- To review the efficacy and clinical development of nintedanib in NSCLC.
Main Methods:
- A Medline search was conducted using keywords related to non-small cell lung cancer and nintedanib (BIBF 1120).
- Searches included ASCO abstracts from 2013 and Phase I/II abstracts concerning nintedanib in lung cancer.
Main Results:
- Nintedanib exhibits significant antiangiogenic and antineoplastic activities.
- In vitro studies show nintedanib prevents tumor growth and overcomes drug resistance.
Conclusions:
- Recent Phase III trials indicate promising efficacy for nintedanib in NSCLC.
- Further investigation is required to establish nintedanib's role in routine clinical practice.
Related Concept Videos
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists